The SARS-CoV-2 virus resulted in a global pandemic and significant loss of lives . Older people are vulnerable to COVID-19 infections and complications, thus are a priority group to receive COVID-19 vaccines . In this review, COVID-19 vaccine considerations for older adults are discussed . General concepts of vaccine effectiveness in older adults are described, particularly immune senescence and vaccine development approaches to improve immunogenicity . The types of COVID-19 vaccine platforms are described before reviewing the available but limited evidence from phase 3 COVID-19 vaccine trials relevant to older adults . The BNT162b2 by Pfizer-BioNTech and mRNA-1273 from Moderna demonstrated high efficacy and immunogenicity, which is also seen in older people . The ChAdOx1 nCoV-19 (AZD1222) vaccine by AstraZeneca demonstrated some efficacy in older people but the vaccine dose requires clarification through further studies . Finally the Ad26.COV2.S by Janssen shows promise as a single-dose vaccine with potential durability of response.